Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $38.87 Analyst target: $133.08 Upside: 242.37%
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
See the full interactive analysis & chart →Informational only — not investment advice.